- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: DU-176 | DU-176b | edoxaban tosylate | Lixiana® | Savaysa®
edoxaban is an approved drug (EMA & FDA (2015))
Compound class: Synthetic organic
Comment: Edoxaban is an oral, once-daily factor Xa inhibitor anticoagulant.
Marketed formulations contain edoxaban tosylate (PubChem CID 44610678).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: edoxaban
|No information available.
|Summary of Clinical Use
|This drug was initially approved in Japan for the treatment of venous thromboembolism (VTE). Subsequently, in 2015, the US FDA and EMA approved edoxaban to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation that is not caused by a heart valve problem and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have already received anti-clotting therapy for five to ten days.
|Mechanism Of Action and Pharmacodynamic Effects
|Edoxaban acts as a direct factor Xa inhibitor. This family of drugs inhibits coagulation without using antithrombin as a mediator.
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)